Table 4.
Univariate and multivariate analysis of the impact of the frailty profile of patients on OS, PFS, discontinuation rate, and incidence of grade 3 or higher toxicity
| OS | PFS | Discontinuation | Grade ≥3 hematologic toxicity | Grade ≥3 nonhematologic toxicity | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Crude | ||||||||||
| Fit | 1 | — | 1 | — | 1 | — | 1 | — | 1 | — |
| Intermediate fitness | 1.61 (1.02-2.56) | .042 | 1.18 (0.91-1.53) | .211 | 1.48 (1.05-2.10) | .026 | 0.97 (0.74-1.27) | .808 | 1.23 (0.89-1.71) | .217 |
| Frail | 3.57 (2.37-5.39) | <.001 | 1.68 (1.31-2.15) | <.001 | 2.27 (1.64-3.14) | <.001 | 0.83 (0.62-1.09) | .181 | 1.74 (1.28-2.38) | <.001 |
| Adjusted* | ||||||||||
| Fit | 1 | — | 1 | — | 1 | — | 1 | — | 1 | — |
| Intermediate fitness | 1.37 (0.86-2.18) | .181 | 1.08 (0.83-1.40) | .583 | 1.41 (1.00-2.01) | .052 | 0.97 (0.74-1.28) | .831 | 1.13 (0.81-1.58) | .462 |
| Frail | 2.88 (1.88-4.40) | <.001 | 1.48 (1.15-1.92) | .003 | 2.21 (1.57-3.09) | <.001 | 0.94 (0.71-1.26) | .698 | 1.57 (1.12-2.19) | .008 |
*
Adjusted for ISS, chromosome abnormalities, and therapy.